These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1964 related items for PubMed ID: 23348694

  • 21. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
    Deng R, Yang F, Chang SH, Tang J, Qin J, Feng GK, Ding K, Zhu XF.
    Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
    [Abstract] [Full Text] [Related]

  • 22. Recombinant human interleukin-24 suppresses gastric carcinoma cell growth in vitro and in vivo.
    Yan S, Zhang H, Xie Y, Sheng W, Xiang J, Ye Z, Chen W, Yang J.
    Cancer Invest; 2010 Jan; 28(1):85-93. PubMed ID: 19916746
    [Abstract] [Full Text] [Related]

  • 23. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
    Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, Park JH, Kang BC, Im SA, Kim TY, Kim WH, Bang YJ.
    Cancer Res; 2008 Mar 15; 68(6):1916-26. PubMed ID: 18339873
    [Abstract] [Full Text] [Related]

  • 24. A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade.
    Chao TH, Tseng SY, Li YH, Liu PY, Cho CL, Shi GY, Wu HL, Chen JH.
    Clin Sci (Lond); 2012 Aug 01; 123(3):147-59. PubMed ID: 22339730
    [Abstract] [Full Text] [Related]

  • 25. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG, Huang H, Chen SM, Chen Y, Xin XL, Lin LP, Ding J, Liu H, Meng LH.
    Breast Cancer Res Treat; 2011 Nov 01; 130(1):85-96. PubMed ID: 21181437
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
    Gu Y, Scheuer C, Feng D, Menger MD, Laschke MW.
    Anticancer Drugs; 2013 Sep 01; 24(8):781-91. PubMed ID: 23744558
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of Src impairs the growth of met-addicted gastric tumors.
    Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.
    Clin Cancer Res; 2010 Aug 01; 16(15):3933-43. PubMed ID: 20628031
    [Abstract] [Full Text] [Related]

  • 28. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H, Jewell JP, Kariv I, Katz JD, Kunii K, Lu W, Lutterbach BA, Paweletz CP, Qu X, Reilly JF, Szewczak AA, Zeng Q, Kohl NE, Dinsmore CJ.
    Cancer Res; 2010 Feb 15; 70(4):1524-33. PubMed ID: 20145145
    [Abstract] [Full Text] [Related]

  • 29. A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer.
    Yuan Q, Cai S, Zhang X, Liu Z, Li Z, Luo X, Xiong C, Wang J, Hu J, Ruan J.
    Cancer Lett; 2012 Nov 28; 324(2):210-20. PubMed ID: 22652174
    [Abstract] [Full Text] [Related]

  • 30. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST.
    Cancer Res; 2005 May 01; 65(9):3691-9. PubMed ID: 15867364
    [Abstract] [Full Text] [Related]

  • 31. Neuromedin B induces angiogenesis via activation of ERK and Akt in endothelial cells.
    Park HJ, Kim SR, Bae SK, Choi YK, Bae YH, Kim EC, Kim WJ, Jang HO, Yun I, Kim YM, Bae MK.
    Exp Cell Res; 2009 Nov 15; 315(19):3359-69. PubMed ID: 19703440
    [Abstract] [Full Text] [Related]

  • 32. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D, Tang F, Wang S, Jiang Z, Zhang L.
    Cancer Chemother Pharmacol; 2012 Jan 15; 69(1):173-83. PubMed ID: 21638122
    [Abstract] [Full Text] [Related]

  • 33. Intermedin: a novel regulator for vascular remodeling and tumor vessel normalization by regulating vascular endothelial-cadherin and extracellular signal-regulated kinase.
    Zhang W, Wang LJ, Xiao F, Wei Y, Ke W, Xin HB.
    Arterioscler Thromb Vasc Biol; 2012 Nov 15; 32(11):2721-32. PubMed ID: 22922959
    [Abstract] [Full Text] [Related]

  • 34. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H, Hori A.
    Mol Cancer Ther; 2013 Jun 15; 12(6):913-24. PubMed ID: 23548264
    [Abstract] [Full Text] [Related]

  • 35. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W, Jin K, Lan H, Han N, Cao F, Teng L.
    Hepatogastroenterology; 2012 Jun 15; 59(120):2543-7. PubMed ID: 22534543
    [Abstract] [Full Text] [Related]

  • 36. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS.
    Prostate Cancer Prostatic Dis; 2012 Mar 15; 15(1):15-27. PubMed ID: 22083267
    [Abstract] [Full Text] [Related]

  • 37. Osteogenesis and angiogenesis induced by porous β-CaSiO(3)/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways.
    Wang C, Lin K, Chang J, Sun J.
    Biomaterials; 2013 Jan 15; 34(1):64-77. PubMed ID: 23069715
    [Abstract] [Full Text] [Related]

  • 38. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L, Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y.
    Clin Cancer Res; 2011 Jul 01; 17(13):4439-50. PubMed ID: 21622720
    [Abstract] [Full Text] [Related]

  • 39. Thio-Cl-IB-MECA, a novel A₃ adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells.
    Kim GD, Oh J, Jeong LS, Lee SK.
    Biochem Biophys Res Commun; 2013 Jul 19; 437(1):79-86. PubMed ID: 23791876
    [Abstract] [Full Text] [Related]

  • 40. Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways.
    Chen ML, Lin YH, Yang CM, Hu ML.
    Mol Nutr Food Res; 2012 Jun 19; 56(6):889-99. PubMed ID: 22707264
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 99.